CD40L–CD40 and CD27–CD70 co-stimulatory pathways (CD40/CD27 pathways)

The CD40L–CD40 and CD27–CD70 pathways are critical co-stimulatory axes within the Tumor Necrosis Factor (TNF) superfamily that coordinate the interaction between innate and adaptive immunity [1, 10, 13]. In the "licensing" model of dendritic cells (DCs), CD40L expressed on activated CD4+ T cells binds to CD40 on DCs, triggering DC maturation and the upregulation of co-stimulatory molecules, most notably CD70 [5, 14, 15]. Subsequently, CD70 on the licensed DC interacts with CD27 on T cells to provide essential signals for T-cell expansion, survival, and the establishment of long-term immunological memory [6, 14, 40]. These pathways are pivotal for effective anti-tumor immune responses and are frequently dysregulated in various cancers and autoimmune conditions [11, 18, 22]. Therapeutically, agonistic antibodies targeting CD40 or CD27 are being developed to enhance the immune system's ability to recognize and destroy tumor cells, often in combination with checkpoint inhibitors [3, 11, 17]. Conversely, antagonistic strategies that block these interactions are explored for treating autoimmune diseases and preventing organ transplant rejection by dampening overactive immune responses [12, 20, 33]. Despite their potential, clinical development faces challenges such as systemic toxicity and the need for precise patient stratification based on target expression [11, 18, 19].

Other names

CD40-CD154 and CD27-CD70 pathwaysTNFRSF5-TNFSF5 and TNFRSF7-TNFSF7 pathwaysDendritic cell licensing axesCD40/CD27 co-stimulatory network

Agonism of CD40 or CD27 to stimulate anti-tumor immunity; Antagonism or blockade of CD40/CD40L to suppress autoimmunity and transplant rejection; Antibody-drug conjugation (ADC) targeting CD70 to induce direct tumor cell killing.